Canadian Company’s New Version Of Chemo-Induced Pain Treatment Is On FDA Track
Drug delivery company IntelGenx Corp.
Cutera’s AviClearTM 12-Month Clinical Data Presented At 42nd Annual Fall Clinical Dermatology Conference
Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, today announced that the 12-month clinical data related to AviClear, the first and
Immix Biopharma To Present Milestones Achieved To Enable Kick-Off Of 2 IMX-110 Clinical Trials At 2022 ThinkEquity Conference On October 26
Immix Biopharma, Inc. (NASDAQ:IMMX) ("ImmixBio", "Company", "We" or "Us"), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)™ targeting oncology
Why Accelerate Diagnostics Shares Are Plummeting Today?
Accelerate Diagnostics Inc (NASDAQ:AXDX) said that according to recent discussions, the FDA has clarified that the company must obtain a 510(k)…
Alpine Immune Sciences Stops Davoceticept Trials In Cancer Indications After Second Patient Death
Alpine Immune Sciences Inc (NASDAQ:ALPN) has voluntarily terminated enrollment in both clinical studies involving davoceticept (ALPN-202), an investigational CD28 costimulator, and…
9 Meters Biopharma Presents Preclinical Data On Glucose-Dependent Insulinotropic Polypeptide Monoclonal Antibodies For Obesity At The American College Of Gastroenterology 2022 Annual Scientific Meeting October 21-26
Preclinical data investigated the use of glucose-dependent insulinotropic polypeptide (GIP) monoclonal antibodies (mAbs) to prevent and treat obesity in animal models
Poster granted Outstanding Research Award
9
Bio-Path Holdings Announces First Patient Dosed In Phase 1/1b Study Of BP1002 In Refractory/Relapsed Acute Myeloid Leukemia Patients
Bio-Path Holdings, Inc., (NASDAQ:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today
AbbVie Announces RINVOQ (Upadacitinib) Receives Sixth U.S. FDA Approval
AbbVie (NYSE:ABBV) today announces that the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib 15 mg, once daily), an oral therapy, for the treatment of adults with active
Accelerate Diagnostics Says Has Been In Recent Discussions With FDA Regarding Accelerate Arc System, Related BC Kit
On October 21, 2022, Accelerate Diagnostics, Inc. (the “Company”) announced it has been in recent discussions with the U.S. Food and Drug Administration (“FDA”) regarding its Accelerate Arc